Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix ABACIXF 40 Price-to-Tangible-Book is 6.63 as of Sep. 04, 2026. GuruFocus rates ACIXF with a GF Score™ of 40/100 and a GF Value™ of $0.02 (Fairly Valued). The stock has 1 warning sign investors should review. Among 702 Medical Devices & Instruments companies, Acarix AB ranks worse than 81.77% on this metric.
As of today (2026-09-04), Acarix AB's share price is $0.0199. Acarix AB's Tangible Book per Share of Jun. 2026 for the quarter that ended in Jun. 2026 was $0.00. Hence, Acarix AB's Price to Tangible Book Ratio of today is 6.63.
The historical rank and industry rank for Acarix AB's Price-to-Tangible-Book or its related term are showing as below:
During the past 12 years, Acarix AB's highest Price to Tangible Book Ratio was 10.77. The lowest was 0.77. And the median was 3.64.
ACIXF's Price-to-Tangible-Book is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.635 * Ranked among companies with meaningful Price-to-Tangible-Book only.
A closely related ratio is called PB Ratio. As of today, Acarix AB's share price is $0.0199. Acarix AB's Book Value per Sharefor the quarter that ended in Jun. 2026 was $0.00. Hence, Acarix AB's P/B Ratio of today is 4.98.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Acarix AB Price-to-Tangible-Book Related Terms
Acarix AB Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Acarix AB's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACIXF vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Acarix AB's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Acarix AB's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Acarix AB (ACIXF) has a Price-to-Tangible-Book of 6.63 as of Sep. 04, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Acarix AB and its competitors. According to the industry distribution chart, Acarix AB ranks #574 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 81.8%.
Is Acarix AB's Price-to-Tangible-Book too high?
Acarix AB's current Price-to-Tangible-Book is 6.63. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.64. Acarix AB's value of 6.63 is 151.6% above this industry median. Based on the distribution chart, Acarix AB ranks #574 out of 702 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Acarix AB has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #574 out of 702 companies for Price-to-Tangible-Book. This places Acarix AB in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.64. Acarix AB's value of 6.63 is 151.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.64, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current Price-to-Tangible-Book of 6.63 is 151.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current Price-to-Tangible-Book is 6.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Fairly Valued. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading 0.5% below its estimated fair value. The current Price-to-Tangible-Book is 6.63 and 151.6% above the Medical Devices & Instruments industry median of 2.64. Acarix AB's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Price-to-Tangible-Book is 6.63 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (ACIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be undervalued.
The current stock price of $0.02 is trading 0.5% below its estimated GF Value™ of $0.02.
GuruFocus considers Acarix AB to be Fairly Valued.
Key valuation signals for ACIXF:
Price-to-Tangible-Book: 6.63
GF Value™: $0.02 vs. price of $0.02 (0.5% below fair value)
Industry Position: 151.6% above the Medical Devices & Instruments median (#574 of 702)
No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
40GF Score
Get the complete analysis for ACIXF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIXF has been successfully added to your 
